Apricus Biosciences Inc (NASDAQ:APRI) fell 7.1% on Monday . The company traded as low as $0.78 and last traded at $0.79. 622,418 shares traded hands during mid-day trading, a decline of 59% from the average session volume of 1,508,486 shares. The stock had previously closed at $0.85.
A number of brokerages recently weighed in on APRI. HC Wainwright downgraded shares of Apricus Biosciences from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research note on Friday, February 16th. Zacks Investment Research downgraded shares of Apricus Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, January 23rd. Finally, ValuEngine raised shares of Apricus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
The company has a market capitalization of $12.01, a P/E ratio of -0.74 and a beta of 0.96.
An institutional investor recently bought a new position in Apricus Biosciences stock. Healthcare Value Capital LLC bought a new stake in Apricus Biosciences Inc (NASDAQ:APRI) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 100,000 shares of the company’s stock, valued at approximately $184,000. Apricus Biosciences makes up about 0.6% of Healthcare Value Capital LLC’s investment portfolio, making the stock its 8th biggest position. Healthcare Value Capital LLC owned about 0.66% of Apricus Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 18.61% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3258148/apricus-biosciences-apri-shares-down-7-1.html.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.